Scilex Holding (NASDAQ:SCLX - Get Free Report) insider Jaisim Shah purchased 32,000 shares of Scilex stock in a transaction that occurred on Tuesday, October 29th. The stock was acquired at an average cost of $0.99 per share, with a total value of $31,680.00. Following the transaction, the insider now owns 109,333 shares in the company, valued at $108,239.67. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Jaisim Shah also recently made the following trade(s):
- On Wednesday, October 16th, Jaisim Shah purchased 30,000 shares of Scilex stock. The stock was acquired at an average cost of $0.99 per share, with a total value of $29,700.00.
Scilex Trading Up 1.3 %
SCLX stock opened at $1.00 on Wednesday. Scilex Holding has a 1-year low of $0.73 and a 1-year high of $2.63. The stock has a market cap of $190.83 million, a P/E ratio of -0.70 and a beta of 1.15. The stock's fifty day simple moving average is $0.99 and its two-hundred day simple moving average is $1.22.
Scilex (NASDAQ:SCLX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02. The company had revenue of $16.37 million for the quarter, compared to the consensus estimate of $13.17 million. As a group, analysts forecast that Scilex Holding will post -0.75 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
When it comes to NVDA… “acceleration cycles” are the key
From DTI | Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options…
By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)...
And thanks to many months and late nights working out the kinks of the systems…
They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!
SCLX has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Scilex in a research report on Monday, October 21st. Alliance Global Partners started coverage on shares of Scilex in a research note on Wednesday, October 16th. They issued a "buy" rating and a $14.00 target price for the company.
Get Our Latest Research Report on Scilex
Institutional Investors Weigh In On Scilex
Large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company bought a new position in Scilex during the second quarter valued at $25,000. Bank of New York Mellon Corp bought a new position in shares of Scilex during the 2nd quarter worth $31,000. XTX Topco Ltd increased its holdings in Scilex by 321.4% in the 2nd quarter. XTX Topco Ltd now owns 105,431 shares of the company's stock worth $203,000 after acquiring an additional 80,409 shares during the last quarter. Donald L. Hagan LLC raised its stake in Scilex by 59.5% in the 2nd quarter. Donald L. Hagan LLC now owns 113,292 shares of the company's stock valued at $219,000 after acquiring an additional 42,245 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Scilex by 1.4% during the first quarter. Vanguard Group Inc. now owns 3,988,265 shares of the company's stock valued at $6,341,000 after purchasing an additional 55,757 shares during the last quarter. Hedge funds and other institutional investors own 69.67% of the company's stock.
About Scilex
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
